Pancreatic Cancer Research

ResearcherAlbany College of Pharmacy and Health SciencesActive in the last 2 years

Shaker A. Mousa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0002-9294-015X; OpenAlex author ID A5032045966. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 13

  1. RETRACTED: Sudha et al. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Se… Last author DOI 10.3390/biomedicines13112641↗
  2. Editorial Expression of Concern: Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Last author DOI 10.1007/s12672-023-00668-5↗
  3. Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation [Retraction]. Last author DOI 10.2147/ijn.s385584↗
  4. RETRACTED: Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Sensitizer in P… Last author DOI 10.3390/biomedicines10040795↗
  5. Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting. First author DOI 10.3390/cancers14122879↗
  6. Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation. Last author DOI 10.2147/ijn.s238256↗
  7. αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model. Last author DOI 10.3389/fphar.2020.00095↗
  8. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. First author DOI 10.1007/s00432-018-2651-3↗
  9. Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. Last author DOI 10.18632/oncotarget.10395↗
  10. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Last author DOI 10.3892/ijo.2014.2803↗
  11. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Last author DOI 10.1016/j.canlet.2014.04.016↗
  12. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Last author DOI 10.1007/s12672-013-0137-y↗
  13. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse m… Last author DOI 10.1007/s10585-012-9461-9↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thangirala Sudha · 11 shared papers, 2012–2025 · strength 1.49
  2. Deena S. Mousa · 2 shared papers, 2020–2022 · strength 0.35
  3. Nardeen Perko · 1 shared paper, 2022 · strength 0.33
  4. Murat Yalçın · 3 shared papers, 2013–2023 · strength 0.26
  5. Catherine M. Sielaff · 1 shared paper, 2018 · strength 0.17
  6. Melis Debreli Coskun · 1 shared paper, 2020 · strength 0.13
  7. Reem Alyahya · 1 shared paper, 2015 · strength 0.06
  8. Mehdi Boroujerdi · 1 shared paper, 2016 · strength 0.06
  9. Vandhana Muralidharan-Chari · 1 shared paper, 2016 · strength 0.06
  10. Hamed Gilzad Kohan · 1 shared paper, 2016 · strength 0.06
  11. Thiruvengadam Arumugam · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.